Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22 ...

Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now ...

Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is ...

Yarrow Bioscience raises $150M; AbbVie's Qulipta succeeds in Phase 3 menstrual migraine trial; Sino Biopharm pays $668M for 5 ...

Compass psilocybin drug reports 13-pt reduction in depression score; Solstice debuts with $225M Series A; Luma unveils $410M ...

Oura's S-1 lays out a push beyond wellness into healthcare, with $1.21B in nine-month revenue and FDA device regulation as a ...

Andy Plump's upcoming retirement marks another major change to Takeda's leadership team after Christophe Weber handed the keys to Julie Kim.

BridgeBio Oncology's stock drops 24% as it narrows BBO-8520 to 2L+ NSCLC, trimming its broader KRAS pipeline plans.

Endpoints News reviews 77 E11 startups; highlights include Candid's $2B UCB buyout, Isomorphic Labs' $2.1B raise, Orca Bio's ...

Lonza breaks ground on an Oregon spray-drying plant, Samsung Bio lands a $262M deal, and Boston Scientific restores supply post-cyberattack.

Cal­i­for­nia-based drug de­vel­op­er Ex­elix­is sub­mit­ted new safe­ty and ef­fi­ca­cy da­ta on its po­ten­tial treat­ment of metasta­t­ic col­orec­tal can­cer (mCRC) to the FDA. The new da­ta led ...

Anthropic posts a corporate development role for life sciences dealmaking, paying up to $600,000, as its biotech push and IPO ...